Ikarian Capital LLC Grows Stake in InflaRx (NASDAQ:IFRX)

Ikarian Capital LLC grew its position in InflaRx (NASDAQ:IFRX) by 2.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 704,987 shares of the company’s stock after purchasing an additional 16,383 shares during the quarter. Ikarian Capital LLC owned about 1.20% of InflaRx worth $1,086,000 at the end of the most recent reporting period.

Separately, Raymond James & Associates grew its holdings in shares of InflaRx by 7.9% during the fourth quarter. Raymond James & Associates now owns 175,279 shares of the company’s stock valued at $286,000 after buying an additional 12,873 shares during the last quarter. Institutional investors and hedge funds own 42.39% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of InflaRx in a report on Monday, June 24th.

InflaRx Stock Up 1.3 %

Shares of IFRX traded up $0.02 during trading hours on Thursday, reaching $1.52. 47,690 shares of the company traded hands, compared to its average volume of 193,069. The stock has a market capitalization of $89.50 million, a P/E ratio of -1.92 and a beta of 1.58. InflaRx has a 12-month low of $1.14 and a 12-month high of $4.30. The business has a fifty day moving average price of $1.57 and a 200-day moving average price of $1.54.

InflaRx (NASDAQ:IFRX) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.05. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $1.76 million. As a group, research analysts predict that InflaRx will post -0.81 EPS for the current fiscal year.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.